Execution of a license agreement with EMS for Sitavig® in Brazil

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

06/25/2014

Merger Plan with Topotarget: Pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financial operations
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

06/20/2014

BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

06/10/2014

Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financial operations
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

05/28/2014

Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo

 DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO  — Onxeo expected to have a […]

• 2014
• Financial operations
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

05/21/2014

Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

05/19/2014

BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Other products
• Press releases

05/05/2014

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financial information
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/30/2014

BioAlliance Pharma Publishes its first Shareholder Newsletter

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

• 2014
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/29/2014

BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company

— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]

• 2014
• Financial operations
• Financials and Corporate
• Press releases

Tags: Financials & Corporate

04/16/2014